Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ERYUF
ADC Name
SGN-B7H4V
Synonyms
PF-08046048; SGN-B7H4V; SGNB 7H4V; SGNB7H4V
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Felmetatug
  Antibody Info 
Antigen Name
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05194072
Phase 1
A phase 1 study of SGN-B7H4V in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Locally advanced unresectable or metastatic solid tumors.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT05194072  Clinical Status Phase 1
Clinical Description A phase 1 study of SGN-B7H4V in advanced solid tumors.
References
Ref 1 First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer. J Clin Oncol. 2020 38:15_suppl, 3551-3551.